342808-41-7

Basic information

• Product Name: 4-Piperidinone, 3,5-bis[(2-fluorophenyl)methylene]-, acetate
• CAS NO: 342808-41-7
• Molecular Formula: C19H15F2NO.C2H4O2
• Molecular Weight: 371.384
• Mol File: 342808-41-7.mol

Chemical Properties

• CAS DataBase Reference: 4-Piperidinone, 3,5-bis[(2-fluorophenyl)methylene]-, acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Piperidinone, 3,5-bis[(2-fluorophenyl)methylene]-, acetate(342808-41-7)
• EPA Substance Registry System: 4-Piperidinone, 3,5-bis[(2-fluorophenyl)methylene]-, acetate(342808-41-7)

Safety Data

• Hazardous Substances Data: 342808-41-7(Hazardous Substances Data)

Upstream product

• 41979-39-9 4-piperidone hydrochloride 
• 64-19-7 acetic acid 
• 446-52-6 2-Fluorobenzaldehyde 

Downstream Products

• 342808-40-6 3,5-bis(2-fluorobenzylidene)piperidin-4-one 
• 1357390-43-2 N'-(5-{2-[3,5-bis-(2-fluorobenzylidene)-4-oxopiperidin-1-yl]ethylcarbamoyl}pyridin-2-yl)hydrazinecarboxylic acid tert-butyl ester 
• 1357390-44-3 N-{2-[3,5-bis-(2-fluorobenzylidene)-4-oxo-piperidin-1-yl]-ethyl}-6-hydrazinonicotinamide 
• 1357390-42-1 1-(2-aminoethyl)-3,5-bis-(2-fluorobenzylidene)-4-piperidone 

Relevant articles and documents

Anticancer Activity of an Imageable Curcuminoid 1-[2-Aminoethyl-(6-hydrazinopyridine-3-carbamidyl)-3,5-bis-(2-fluorobenzylidene)-4-piperidone (EFAH)

3,5-Bis(2-fluorobenzylidine)-4-piperidone or EF24 is a potent anticancer derivative of curcumin. Using an amine derivative of EF24, we synthesized a hydrazinonicotinic acid conjugate, EFAH, for Tc-99m radiolabelling and single photon emission tomography imaging. The aqueous solubility of EFAH (3.5mg/mL) was significantly more than that of EF24 (1.2mg/mL); the octanol/water partition coefficient of EFAH was estimated at log P=0.33. As an antiproliferative agent, EFAH was as effective as EF24 in suppressing the proliferation of H441, MiaPaCa-2 and Panc-1 cells. Daily intraperitoneal injection of EFAH (5μg) for 3weeks in mice carrying xenografts of Panc-1 pancreatic cancer showed a mean tumour volume reduction of 79%; the tumour weight decreased by 82% in the treated group. For imaging and biodistribution, EFAH was labelled with Tc-99m (98% RCY) and intravenously administered in rats. Approximately 23.7% and 14.3% of injected dose accumulated in liver and intestine, respectively, suggesting that EFAH is mostly eliminated by hepatobiliary route. The results indicate that HYNIC modification of EF24 for Tc-99m radiolabelling does not affect its antiproliferative efficacy. For the first time, a visual biodisposition of EF24 in a live animal model has been demonstrated. Such knowledge could be of benefit in developing therapeutic curcuminoids, such as EF24.